Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 28, 2015; 21(16): 4933-4945
Published online Apr 28, 2015. doi: 10.3748/wjg.v21.i16.4933
Published online Apr 28, 2015. doi: 10.3748/wjg.v21.i16.4933
Table 1 Characteristics of hepatocellular carcinoma patients with hepatitis B virus infection
Variables | All patients (n = 105) | LL group (n = 55) | HL group (n = 34) | HH group (n = 16) | P value |
Age (yr) | 62 (57-68) | 62 (59-66) | 64 (56-70) | 63 (56-70) | 0.962 |
Sex, male/female | 90/15 | 48/7 | 29/5 | 13/3 | 0.829 |
Body mass index (kg/m2) | 23.7 ± 3.1 | 24.0 ± 2.6 | 23.5 ± 3.3 | 23.1 ± 4.3 | 0.691 |
Open/pure lap/lap-assisted | 83/8/14 | 43/6/6 | 29/1/4 | 11/1/4 | 0.390 |
Hr | |||||
0/S/1/2/3 | 50/25/14/14/2 | 34/13/6/2/0 | 14/10/4/4/2 | 2/2/4/8/0 | < 0.001 |
Preoperative laboratory values | |||||
Aspartate transaminase (U/L) | 31 (22-46) | 31 (22-41) | 30 (25-48) | 43 (24-62) | 0.153 |
Alanine transaminase (U/L) | 29 (20-39) | 32 (17-42) | 27 (21-42) | 27 (19-52) | 0.978 |
Platelets (× 104/μL) | 16.6 ± 13.3 | 16.4 ± 12.7 | 16.2 ± 16.2 | 18.0 ± 8.6 | 0.168 |
Serum ALB (g/dL) | 3.95 ± 0.46 | 3.99 ± 0.46 | 3.87 ± 0.43 | 3.98 ± 0.53 | 0.334 |
PT (%) | 93.3 ± 12.2 | 95.5 ± 11.1 | 90.3 ± 14.1 | 92.2 ± 10.6 | 0.062 |
Serum TBIL (mg/dL) | 0.79 ± 0.44 | 0.80 ± 0.45 | 0.85 ± 0.49 | 0.65 ± 0.24 | 0.681 |
ICGR15 | 9.6 (5.7-14.9) | 9.4 (5.9-14.0) | 12.5 (5.7-22.5) | 8.5 (5.0-14.6) | 0.334 |
AFP (ng/mL) | 24.2 (3.8-165.0) | 5.2 (2.4-31.1) | 45.0 (5.1-246.5) | 1950 (753.5-2827.0) | < 0.001 |
DCP (mAU/mL) | 38 (20-364) | 22 (15-28) | 399 (90-1,667) | 4460 (223-34373) | < 0.001 |
Intraoperative data | |||||
Blood loss (mL) | 400 (130-660) | 360 (110-560) | 435 (100-1,040) | 880 (130-1330) | 0.042 |
Surgical duration (min) | 332 (243-411) | 313 (236-370) | 361 (243-450) | 432 (270-604) | 0.020 |
Blood transfusion | |||||
RCC: yes/no (%) | 21/84 (20.0%) | 4/51 (7.2%) | 10/24 (29.4%) | 7/9 (43.8%) | 0.001 |
Pathological results | |||||
Tumor size (cm) | 4.27 ± 3.21 | 3.26 ± 2.56 | 4.97 ± 2.71 | 6.24 ± 4.77 | < 0.001 |
Multiple tumors: yes/no (%) | 39/66 (37.1%) | 19/36 (34.5%) | 15/19 (44.1%) | 5/11 (31.3%) | 0.575 |
Vascular invasion: yes/no (%) | 34/71 (32.4%) | 10/45 (18.2%) | 14/20 (41.1%) | 10/6 (62.5%) | 0.002 |
Remnant liver: NL/CH/LC | 13/47/41 | 6/23/26 | 3/17/14 | 4/7/5 | 0.464 |
Histological tumor differentiation | |||||
Well/moderately/poorly | 14/63/28 | 11/35/9 | 3/18/13 | 0/10/6 | 0.048 |
Recurrence within 2 yr after liver resection | |||||
Yes/no (%) | 50/55 (47.6%) |
Table 2 Univariate and multivariate analyses of factors associated with tumor recurrence in patients with hepatitis B virus infection
Variables | Univariate analysis | Multivariate analysis | ||||
HR | 95%CI | P value | HR | 95%CI | P value | |
Age | 0.977 | 0.952-1.003 | 0.086 | |||
Sex, male | 1.077 | 0.512-2.264 | 0.843 | |||
Preoperative laboratory values | ||||||
Aspartate transaminase | 1.008 | 1.003-1.013 | 0.0011 | 1.001 | 0.993-1.010 | 0.778 |
Alanine transaminase | 0.999 | 0.989-1.009 | 0.811 | |||
Platelets | 1.001 | 0.979-1.024 | 0.929 | |||
Serum ALB | 0.648 | 0.367-1.142 | 0.134 | |||
PT | 0.974 | 0.953-0.996 | 0.0211 | 0.976 | 0.946-1.007 | 0.124 |
Serum TBIL | 2.305 | 1.346-3.947 | 0.0021 | 4.068 | 1.586-10.436 | 0.0041 |
ICGR15 | 1.033 | 1.008-1.059 | 0.0111 | 0.967 | 0.919-1.018 | 0.967 |
Tumor markers | ||||||
HH group | 3.235 | 1.673-6.257 | < 0.0011 | 2.464 | 1.086-5.587 | 0.0311 |
HL group | 2.042 | 1.164-3.583 | 0.0131 | 1.083 | 0.497-2.360 | 0.841 |
Intraoperative data | ||||||
Blood loss | 1.001 | 1.000-1.001 | 0.0021 | 1.000 | 1.000-1.001 | 0.416 |
Surgical duration | 1.002 | 1.000-1.004 | 0.0031 | 1.000 | 0.997-1.003 | 0.868 |
Pathologic results | ||||||
Tumor size | 1.148 | 1.068-1.234 | < 0.0011 | 1.182 | 1.059-1.318 | 0.0031 |
Multiple tumors | 1.363 | 1.152-1.612 | < 0.0011 | 1.336 | 0.955-1.869 | 0.091 |
Vascular invasion | 2.088 | 1.261-3.458 | 0.0041 | 2.624 | 1.408-4.892 | 0.0021 |
Table 3 Univariate and multivariate analyses of factors associated with poor overall survival in patients with hepatitis B virus infection
Variables | Univariate analysis | Multivariate analysis | ||||
HR | 95%CI | P value | HR | 95%CI | P value | |
Age | 0.996 | 0.964-1.028 | 0.797 | |||
Sex, male | 1.440 | 0.511-4.056 | 0.490 | |||
Preoperative laboratory values | ||||||
Aspartate transaminase | 1.008 | 1.002-1.014 | 0.0121 | 1.004 | 0.992-1.016 | 0.518 |
Alanine transaminase | 0.992 | 0.976-1.007 | 0.296 | |||
Platelets | 1.015 | 0.994-1.035 | 0.158 | |||
Serum ALB | 0.469 | 0.234-0.939 | 0.033 | |||
PT | 0.975 | 0.950-1.000 | 0.051 | |||
Serum TBIL | 2.249 | 1.125-4.495 | 0.0221 | 1.584 | 0.447-5.613 | 0.476 |
ICGR15 | 1.056 | 1.025-1.087 | < 0.0011 | 1.040 | 0.976-1.108 | 0.229 |
Tumor markers | ||||||
HH group | 2.985 | 1.259-7.075 | 0.0131 | 2.274 | 0.698-7.403 | 0.173 |
HL group | 2.112 | 1.054-4.232 | 0.0351 | 1.025 | 0.390-2.693 | 0.960 |
Intraoperative data | ||||||
Blood loss | 1.001 | 1.001-1.001 | < 0.0011 | 1.000 | 1.000-1.001 | 0.391 |
Surgical duration | 1.004 | 1.001-1.008 | 0.0051 | 1.002 | 0.996-1.007 | 0.534 |
Pathologic results | ||||||
Tumor size | 1.239 | 1.133-1.356 | < 0.0011 | 1.127 | 0.969-1.310 | 0.122 |
Multiple tumors | 1.385 | 1.121-1.711 | 0.0021 | 1.200 | 0.813-1.772 | 0.358 |
Vascular invasion | 2.491 | 1.335-4.647 | 0.0041 | 3.173 | 1.352-7.447 | 0.0081 |
Table 4 Characteristics of hepatocellular carcinoma patients with hepatitis C virus infection
Variables | All patients (n = 100) | LL group (n = 34) | HL group (n = 39) | HH group (n = 27) | P value |
Age (yr) | 71 (62-77) | 72 (64-77) | 70 (62-75) | 70 (65-77) | 0.766 |
Sex, male/female | 82/18 | 22/12 | 29/10 | 16/11 | 0.413 |
Body mass index | 23.6 ± 3.6 | 23.6 ± 2.9 | 23.8 ± 3.8 | 23.4 ± 4.1 | 0.737 |
Open/Pure Lap/Lap-assisted | 77/12/11 | 26/3/5 | 27/8/4 | 24/1/2 | 0.218 |
Hr | |||||
0/S/1/2/3 | 57/27/11/2/3 | 23/8/3/0/0 | 21/10/5/1/2 | 13/9/3/1/1 | 0.784 |
Preoperative laboratory values | |||||
Aspartate transaminase (U/L) | 47 (30-64) | 41 (23-56) | 48 (35-67) | 53 (47-71) | 0.101 |
Alanine transaminase (U/L) | 38 (26-57) | 33 (21-53) | 41 (28-57) | 42 (29-62) | 0.496 |
Platelets (× 104/μL) | 13.5 ± 6.8 | 13.9 ± 4.7 | 13.9 ± 9.2 | 12.5 ± 4.4 | 0.804 |
Serum ALB (g/dL) | 3.76 ± 0.39 | 3.94 ± 0.40 | 3.67 ± 0.35 | 3.67 ± 0.38 | 0.0061 |
PT (%) | 89.8 ± 13.4 | 92.5 ± 11.4 | 87.8 ± 15.0 | 89.2 ± 13.5 | 0.254 |
Serum TBIL (mg/dL) | 0.78 ± 0.34 | 0.74 ± 0.32 | 0.79 ± 0.33 | 0.81 ± 0.39 | 0.777 |
ICGR15 | 14.2 (8.4-18.5) | 12.1 (8.1-15.4) | 14.7 (8.4-21.5) | 15.6 (13.0-24.6) | 0.163 |
AFP (ng/mL) | 18.6 (5.6-134.0) | 5.3 (3.8-11.0) | 21.1 (6.9-99.2) | 299.7 (68.1-1046.0) | < 0.0011 |
DCP (mAU/mL) | 45 (21-244) | 22 (15-35) | 37 (23-134) | 429 (124-1902) | < 0.0011 |
Intraoperative data | |||||
Blood loss (mL) | 330 (20-650) | 263 (70-500) | 230 (20-500) | 535 (300-1270) | 0.0061 |
Surgical duration (min) | 304 (230-377) | 303 (175-377) | 296 (230-352) | 345 (282-475) | 0.0401 |
Blood transfusion | |||||
RCC: yes/no (%) | 12/88 (12.0%) | 3/31 (8.8%) | 2/37 (5.1%) | 7/20 (25.9%) | 0.0301 |
Pathologic results | |||||
Tumor size (cm) | 3.51 ± 2.48 | 2.84 ± 1.23 | 3.26 ± 2.31 | 4.72 ± 3.39 | 0.0081 |
Multiple tumor: yes/no (%) | 36/64 (36.0%) | 8/26 (23.5%) | 17/22 (43.6%) | 11/16 (40.7%) | 0.171 |
Vascular invasion: yes/no (%) | 30/70 (30.0%) | 5/29 (14.7%) | 12/27 (30.8%) | 13/14 (48.1%) | 0.0181 |
Remnant liver: NL/CH/LC | 5/37/58 | 2/18/14 | 2027/10/2 | 2017/9/1 | 0.161 |
Histological tumor differentiation | |||||
Well/Moderately/Poorly | 17/63/20 | 7/23/4 | 8/24/7 | 2/16/9 | 0.213 |
Recurrence within 2 yr after hepatectomy | |||||
Yes/no (%) | 51/49 (51.0%) |
Table 5 Univariate and multivariate analyses of factors associated with tumor recurrence in patients with hepatitis C virus infection
Variables | Univariate analysis | Multivariate analysis | ||||
HR | 95%CI | P value | HR | 95%CI | P value | |
Age | 1.001 | 0.972-1.031 | 0.950 | |||
Sex, male | 1.455 | 0.823-2.570 | 0.197 | |||
Preoperative laboratory values | ||||||
Aspartate transaminase | 1.005 | 0.999-1.011 | 0.134 | |||
Alanine transaminase | 1.003 | 0.966-1.010 | 0.412 | |||
Platelets | 1.015 | 0.983-1.049 | 0.363 | |||
Serum ALB | 0.569 | 0.297-1.092 | 0.090 | |||
PT | 0.999 | 0.980-1.019 | 0.943 | |||
Serum TBIL | 1.281 | 0.610-2.692 | 0.513 | |||
ICGR15 | 1.049 | 1.017-1.081 | 0.0021 | 1.069 | 1.032-1.108 | < 0.0011 |
Tumor markers | ||||||
HH group | 4.427 | 2.238-8.760 | < 0.0011 | 5.098 | 2.165-12.005 | < 0.0011 |
HL group | 2.210 | 1.166-4.189 | 0.0151 | 2.325 | 1.077-5.018 | 0.0321 |
Intraoperative data | ||||||
Blood loss | 1.001 | 1.000-1.001 | < 0.0011 | 1.000 | 0.999-1.000 | 0.292 |
Surgical duration | 1.003 | 1.002-1.004 | < 0.0011 | 1.002 | 0.998-1.006 | 0.129 |
Pathologic results | ||||||
Tumor size | 1.290 | 1.178-1.413 | < 0.0011 | 1.160 | 1.033-1.302 | 0.0121 |
Multiple tumors | 1.264 | 1.073-1.487 | 0.0051 | 1.264 | 1.041-1.534 | 0.0181 |
Vascular invasion | 2.454 | 1.479-4.071 | 0.0011 | 1.597 | 0.890-2.867 | 0.117 |
Table 6 Univariate and multivariate analyses of factors associated with poor overall survival in patients with hepatitis C virus infection
Variables | Univariate analysis | Multivariate analysis | ||||
HR | 95%CI | P value | HR | 95%CI | P value | |
Age | 1.025 | 0.987-1.065 | 0.195 | |||
Sex, male | 1.328 | 0.668-2.642 | 0.418 | |||
Preoperative laboratory values | ||||||
Aspartate transaminase | 1.006 | 0.999-1.013 | 0.106 | |||
Alanine transaminase | 1.001 | 0.992-1.009 | 0.849 | |||
Platelets | 1.036 | 0.995-1.077 | 0.084 | |||
Serum ALB | 0.246 | 0.114-0.531 | < 0.0011 | 0.611 | 0.219-1.706 | 0.347 |
PT | 0.994 | 0.971-1.018 | 0.643 | |||
Serum TBIL | 1.206 | 0.523-2.780 | 0.660 | |||
ICGR15 | 1.054 | 1.021-1.087 | 0.0011 | 1.042 | 1.001-1.084 | 0.0471 |
Tumor markers | ||||||
HH group | 4.562 | 2.031-10.248 | < 0.0011 | 4.018 | 1.424-11.337 | 0.0091 |
HL group | 2.049 | 0.911-4.609 | 0.083 | 2.209 | 0.829-5.885 | 0.113 |
Intraoperative data | ||||||
Blood loss | 1.001 | 1.000-1.001 | < 0.0011 | 1.000 | 0.999-1.001 | 0.727 |
Surgical duration | 1.003 | 1.002-1.004 | < 0.0011 | 1.002 | 0.998-1.005 | 0.414 |
Pathologic results | ||||||
Tumor size | 1.285 | 1.162-1.421 | < 0.0011 | 1.081 | 0.946-1.235 | 0.255 |
Multiple tumors | 1.204 | 1.021-1.420 | 0.0271 | 1.257 | 1.025-1.542 | 0.0281 |
Vascular invasion | 2.223 | 1.221-4.045 | 0.0091 | 1.089 | 0.490-2.421 | 0.835 |
- Citation: Meguro M, Mizuguchi T, Nishidate T, Okita K, Ishii M, Ota S, Ueki T, Akizuki E, Hirata K. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients. World J Gastroenterol 2015; 21(16): 4933-4945
- URL: https://www.wjgnet.com/1007-9327/full/v21/i16/4933.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i16.4933